Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 12 Dec 2013 |
| Major Shareholder Announcement | 11 Dec 2013 |
| Genmab Reaches Fourth Milestone in Lundbeck Collaboration | 6 Dec 2013 |
| Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen – Financial Guidance Improved | 6 Dec 2013 |
| Grant of Warrants to Board Members, Management and Employees in Genmab | 6 Dec 2013 |